A groundbreaking experimental drug, lepodisiran from Eli Lilly, shows promising results in reducing lipoprotein(a) or Lp(a)—a cholesterol variant linked to heart attacks—by an astounding 94% with a single injection. Benefits from this treatment can last up to six months without significant side effects, paving the way for hope in heart health. Despite these findings being presented at the American College of Cardiology, more extensive clinical trials are necessary to confirm the drug’s potential to reduce heart attack risks, with larger trials expected to yield results by 2029.
The nature of Lp(a) is concerning; it’s a dense sub-type of cholesterol that contributes significantly to arterial plaque buildup, increasing the chances of recurrent heart problems. Dr Balbir Singh highlights its relation to inflammation and its interaction with LDL cholesterol, which can narrow the aorta. With Indians often suffering from conditions like high blood pressure and diabetes, particularly those with familial genes linked to Lp(a), vigilance is crucial.
To assess Lp(a) levels, one must undergo an extended lipid profile test, as Dr Singh advises that ideal levels should be below 25mg/dL. Individuals with markers like diabetes or low HDL are at a higher risk of high Lp(a). Screening is vital, especially for those with a family history of heart disease, as it is often genetically inherited.
Currently available treatments, like PCSK9 inhibitors, can lower Lp(a) levels to an extent but do not sufficiently prevent heart attacks. As Dr Chandra notes, the primary goal is to lower the function of Lp(a) through managing low-density LDL levels. Given that while total LDL levels in Indians may be lower than those in Caucasians, the higher presence of small density LDL proves to be more harmful, there’s an urgent need for aggressive reduction of LDL levels below 50 mg/dL.
Eli Lilly’s lepodisiran has been shown to reduce the cholesterol variant Lp(a) by 94% with a single injection, lasting up to six months without side effects. Larger clinical trials are needed to establish its efficacy in heart attack prevention. Lp(a) is linked to high plaque levels, particularly concerning for Indians with diabetes or high blood pressure. Testing for Lp(a) is crucial, and existing treatments may not fully prevent heart attacks, highlighting the need for lowering LDL cholesterol levels.
Eli Lilly’s lepodisiran presents a potential breakthrough in heart health, targeting Lp(a) effectively. While initial trials are promising, the true impact on heart attack prevention awaits further research. Given the genetic ties of Lp(a) to many health issues faced by Indians, early testing and proactive management of cholesterol levels remain essential to safeguard heart health.
Original Source: indianexpress.com
